Page 11 - Dyslipidaemia_newsletter8_2024_Final

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #8 2024

The moderate-intensity statin plus ezetimibe group achieved significantly lower LDL-C levels compared to the high-intensity statin
group at the end of the follow-up period. The low-intensity statin plus ezetimibe group had similar achieved LDL-C levels to the high-
intensity statin group.
Dyslipidaemia

Although not statistically significant, the combination therapy groups tended to have a higher proportion of prescription days covered
compared to the high-intensity statin monotherapy groups, suggesting potentially better adherence.

Comparison of HR for CV events and all-cause mortality in cohort 1
(moderate-intensity statin plus ezetimibe and the high-intensity statin groups)

These findings, consistent with prior research suggesting the
effectiveness of ezetimibe as an adjunct to statin therapy,
indicate that combining statins with ezetimibe, even at lower
statin intensities, can be a valuable strategy for primary CVD
prevention. It is important to note, however, that this was an
observational study and not a randomised controlled trial,
limiting the ability to definitively establish causal relationships.

CLICK HERE
TO READ AN INTERESTING
COMMENTARY BY DR. DE BUYZERE ON
WHETHER THIS RESEARCH, ALONG
WITH OTHER RECENT RESULTS FROM
SIMILAR TRIALS, WILL RESULT IN A
CLICK HERE PARADIGM SHIFT IN LIPID-LOWERING
FOR THE LINK TO FULL ARTICLE IN PRIMARY PREVENTION.

TABLE OF CONTENTS